Monitoring Parameters beyond Glycemic Control: Impact of Treviamet® & Treviamet XR® on Quality of Life in Type 2 DM Patients.
DQoL study was designed to assess the improvement in quality of life besides glycemic control among type 2 diabetes mellitus patients receiving Treviamet® & Treviamet XR® (Sitagliptin with Metformin) in routine care. Duration of study was 12 months (data lock point will be the completion of 6 months of follow-up from the time of last patient's enrollment date). Study Treatment included Sitagliptin + Metformin (Treviamet® pharmaceutical brand used locally). The safety assessment included presence of Hypoglycemia, Nausea, Vomiting, Diarrhea, Abdominal Discomfort, Flatulence, Asthenia, Indigestion Patient was supposed to have three visits for follow-ups. Visit 1 at 4 to 6 weeks of initiation of therapy, visit 2 at 12 weeks and visit 3 at 24 weeks of initiation of therapy. We report differences in the mean HbA1c and FPG levels offered a 6-month treatment. Sitagliptin treatment for glycemic control also improves patient satisfaction leading to improved QoL, is a reasonable hypothesis, which is the primary endpoint assessed in the present study. It was observed that after 24 weeks of Sitagliptin medication, the QoL scores improved. The scores of satisfaction, impact and worry were considerably changed during the course of treatment.